Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against <i>Plasmodium falciparum</i> and In Vivo against Murine Malaria

25 Jan 2006

Abstract excerpt

Parasite resistance to antimalarial drugs is a serious threat to human health, and novel agents that act on enzymes essential for parasite metabolism, such as proteases, are attractive targets for drug development. Recent studies have shown that clinically utilized human immunodeficiency virus (HIV) protease inhibitors can inhibit the in vitro growth of Plasmodium falciparum at or below concentrations found in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Research and Treatment
Share to Malaria Research and Control
Share to Mosquito-borne diseases and control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16436721
DOI: 10.1128/aac.50.2.639-648.2006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against <i>Plasmodium falciparum</i> and In Vivo against Murine MalariaPMID 16436721Read ↗

The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of MalariaSemantic proximity Read ↗

Structure-based design of AIDS drugs and the development of resistance.Semantic proximity Read ↗

Modeling and resistant alleles explain the selectivity of antimalarial compound 49c towards apicomplexan aspartyl proteases.Semantic proximity Read ↗

Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets.Semantic proximity Read ↗

Improved Murine Model of Malaria Using<i>Plasmodium falciparum</i>Competent Strains and Non-Myelodepleted NOD-<i>scid IL2R</i>γ<sup><i>null</i></sup>Mice Engrafted with Human ErythrocytesSemantic proximity Read ↗

Genetic and chemical validation of <i>Plasmodium falciparum</i> aminopeptidase <i>Pf</i> A-M17 as a drug target in the hemoglobin digestion pathwaySemantic proximity Read ↗

Esterase mutation is a mechanism of resistance to antimalarial compounds.Semantic proximity Read ↗

A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmissionSemantic proximity Read ↗

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against the Human Malaria Parasite <i>Plasmodium falciparum</i> via Polypharmacological Inhibition of <i>Pf</i> Ark1 and Hemozoin FormationSemantic proximity Read ↗

A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human ErythrocytesSemantic proximity Read ↗

Plasmodium falciparum Histo-Aspartic Protease (HAP) inhibitor: Toxicity Investigation and Docking Study of 2-(2-benzoyl-4-methylphenoxy)quinoline-3-carbaldehyde derivativesSemantic proximity Read ↗

Novel Inhibitors of Plasmodium Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and In Vivo Efficacy in a Humanized Mouse Malaria Infection ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.